Even though our study is limited only to humoral aspect of immunity, it seems that SARS‐CoV‐2 pediatric patients exhibit SARS‐CoV‐2‐specific antibody responses which are quite comparable regarding antigen, epitope recognition, and the ability to inhibit the RBD‐ACE2 interaction to that of adult patients after mild COVID‐19. The gene discussed is ACE2; the disease is COVID-19.